A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma

Jen Shi Chen, Yee Chao, Tseng Sheng Yang, Wen Chi Chou, Li Tzong Chen, Kuan Der Lee, Yang Chung Lin

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: Advanced biliary tract carcinoma (BTC) is a dismal disease with no standard chemotherapy. We investigated efficacy and toxicity of biweekly oxaliplatin with 48-h infusion of 5-FU/LV in advanced BTC. Methods: All patients had histologic confirmation of BTC, at least one measurable site of disease, and had received no prior chemotherapy. Patients were older than 20 years with ECOG performance scores (PS) of 0-2. Treatment involved 2-h infusion of oxaliplatin (85 mg/m2) diluted in D5W 500 ml followed by 48-h infusion of 5-FU (3,000 mg/m2) and LV (100 mg/m2) biweekly. Response evaluation was based on RECIST criteria and was carried out every two courses of treatment; toxicity evaluation was based on NCI common toxicity criteria version 3.0. Results: From August 2005 to December 2006, 34 chemotherapy-naive patients with advanced BTC were enrolled and 32 intention-to-treat patients were evaluated. Partial response was 18.8%, stable disease was 31.3%, resulting in a disease control rate of 50.0%. Median time to progression and survival was 3.7 and 7 months, respectively. The most common grade 3/4 toxicities were neutropenia 15.6% (5/32), stomatitis 9.4% (3/32), thrombocytopenia 6.3% (2/32), diarrhea 6.3% (2/32) and neuropathy 3.1% (1/32). No treatment-related deaths occurred. Conclusions: The biweekly OXA and 48-h infusion of 5-FU/LV in patients with advanced BTC showed tolerable and efficacy equivalent to other combination regimens treatment.

Original languageEnglish
Pages (from-to)151-157
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume65
Issue number1
DOIs
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

oxaliplatin
Biliary Tract
Fluorouracil
Chemotherapy
Toxicity
Appointments and Schedules
Carcinoma
Drug Therapy
Disease control
Stomatitis
Therapeutics
Neutropenia
Diarrhea

Keywords

  • 5-Fluorouracil
  • Biliary tract cancer
  • Chemotherapy
  • Leucovorin
  • Oxaliplatin

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma. / Chen, Jen Shi; Chao, Yee; Yang, Tseng Sheng; Chou, Wen Chi; Chen, Li Tzong; Lee, Kuan Der; Lin, Yang Chung.

In: Cancer Chemotherapy and Pharmacology, Vol. 65, No. 1, 2009, p. 151-157.

Research output: Contribution to journalArticle

Chen, Jen Shi ; Chao, Yee ; Yang, Tseng Sheng ; Chou, Wen Chi ; Chen, Li Tzong ; Lee, Kuan Der ; Lin, Yang Chung. / A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma. In: Cancer Chemotherapy and Pharmacology. 2009 ; Vol. 65, No. 1. pp. 151-157.
@article{fa0b66bc6ef044798ac259e201ffd648,
title = "A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma",
abstract = "Purpose: Advanced biliary tract carcinoma (BTC) is a dismal disease with no standard chemotherapy. We investigated efficacy and toxicity of biweekly oxaliplatin with 48-h infusion of 5-FU/LV in advanced BTC. Methods: All patients had histologic confirmation of BTC, at least one measurable site of disease, and had received no prior chemotherapy. Patients were older than 20 years with ECOG performance scores (PS) of 0-2. Treatment involved 2-h infusion of oxaliplatin (85 mg/m2) diluted in D5W 500 ml followed by 48-h infusion of 5-FU (3,000 mg/m2) and LV (100 mg/m2) biweekly. Response evaluation was based on RECIST criteria and was carried out every two courses of treatment; toxicity evaluation was based on NCI common toxicity criteria version 3.0. Results: From August 2005 to December 2006, 34 chemotherapy-naive patients with advanced BTC were enrolled and 32 intention-to-treat patients were evaluated. Partial response was 18.8{\%}, stable disease was 31.3{\%}, resulting in a disease control rate of 50.0{\%}. Median time to progression and survival was 3.7 and 7 months, respectively. The most common grade 3/4 toxicities were neutropenia 15.6{\%} (5/32), stomatitis 9.4{\%} (3/32), thrombocytopenia 6.3{\%} (2/32), diarrhea 6.3{\%} (2/32) and neuropathy 3.1{\%} (1/32). No treatment-related deaths occurred. Conclusions: The biweekly OXA and 48-h infusion of 5-FU/LV in patients with advanced BTC showed tolerable and efficacy equivalent to other combination regimens treatment.",
keywords = "5-Fluorouracil, Biliary tract cancer, Chemotherapy, Leucovorin, Oxaliplatin",
author = "Chen, {Jen Shi} and Yee Chao and Yang, {Tseng Sheng} and Chou, {Wen Chi} and Chen, {Li Tzong} and Lee, {Kuan Der} and Lin, {Yang Chung}",
year = "2009",
doi = "10.1007/s00280-009-1018-5",
language = "English",
volume = "65",
pages = "151--157",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma

AU - Chen, Jen Shi

AU - Chao, Yee

AU - Yang, Tseng Sheng

AU - Chou, Wen Chi

AU - Chen, Li Tzong

AU - Lee, Kuan Der

AU - Lin, Yang Chung

PY - 2009

Y1 - 2009

N2 - Purpose: Advanced biliary tract carcinoma (BTC) is a dismal disease with no standard chemotherapy. We investigated efficacy and toxicity of biweekly oxaliplatin with 48-h infusion of 5-FU/LV in advanced BTC. Methods: All patients had histologic confirmation of BTC, at least one measurable site of disease, and had received no prior chemotherapy. Patients were older than 20 years with ECOG performance scores (PS) of 0-2. Treatment involved 2-h infusion of oxaliplatin (85 mg/m2) diluted in D5W 500 ml followed by 48-h infusion of 5-FU (3,000 mg/m2) and LV (100 mg/m2) biweekly. Response evaluation was based on RECIST criteria and was carried out every two courses of treatment; toxicity evaluation was based on NCI common toxicity criteria version 3.0. Results: From August 2005 to December 2006, 34 chemotherapy-naive patients with advanced BTC were enrolled and 32 intention-to-treat patients were evaluated. Partial response was 18.8%, stable disease was 31.3%, resulting in a disease control rate of 50.0%. Median time to progression and survival was 3.7 and 7 months, respectively. The most common grade 3/4 toxicities were neutropenia 15.6% (5/32), stomatitis 9.4% (3/32), thrombocytopenia 6.3% (2/32), diarrhea 6.3% (2/32) and neuropathy 3.1% (1/32). No treatment-related deaths occurred. Conclusions: The biweekly OXA and 48-h infusion of 5-FU/LV in patients with advanced BTC showed tolerable and efficacy equivalent to other combination regimens treatment.

AB - Purpose: Advanced biliary tract carcinoma (BTC) is a dismal disease with no standard chemotherapy. We investigated efficacy and toxicity of biweekly oxaliplatin with 48-h infusion of 5-FU/LV in advanced BTC. Methods: All patients had histologic confirmation of BTC, at least one measurable site of disease, and had received no prior chemotherapy. Patients were older than 20 years with ECOG performance scores (PS) of 0-2. Treatment involved 2-h infusion of oxaliplatin (85 mg/m2) diluted in D5W 500 ml followed by 48-h infusion of 5-FU (3,000 mg/m2) and LV (100 mg/m2) biweekly. Response evaluation was based on RECIST criteria and was carried out every two courses of treatment; toxicity evaluation was based on NCI common toxicity criteria version 3.0. Results: From August 2005 to December 2006, 34 chemotherapy-naive patients with advanced BTC were enrolled and 32 intention-to-treat patients were evaluated. Partial response was 18.8%, stable disease was 31.3%, resulting in a disease control rate of 50.0%. Median time to progression and survival was 3.7 and 7 months, respectively. The most common grade 3/4 toxicities were neutropenia 15.6% (5/32), stomatitis 9.4% (3/32), thrombocytopenia 6.3% (2/32), diarrhea 6.3% (2/32) and neuropathy 3.1% (1/32). No treatment-related deaths occurred. Conclusions: The biweekly OXA and 48-h infusion of 5-FU/LV in patients with advanced BTC showed tolerable and efficacy equivalent to other combination regimens treatment.

KW - 5-Fluorouracil

KW - Biliary tract cancer

KW - Chemotherapy

KW - Leucovorin

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=70349617463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349617463&partnerID=8YFLogxK

U2 - 10.1007/s00280-009-1018-5

DO - 10.1007/s00280-009-1018-5

M3 - Article

VL - 65

SP - 151

EP - 157

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -